recognizing parties operating paragraph article must reduce consumption annex a group i controlled substances chlorofluorocarbons per cent baseline complete phase out substances january including chlorofluorocarbons used metered dose inhalers treatment asthma chronic obstructive pulmonary disease bearing mind that according paragraph decision iv essential use controls applicable parties operating paragraph article phase out dates applicable parties recognizing potential uncertainty supplies pharmaceutical grade chlorofluorocarbons near future impact people health local businesses national manufacturing plants depend imports substances cannot predict availability aware phase out chlorofluorocarbon metered dose inhalers parties operating paragraph article likely complete phase out deadline parties operating article metered dose inhalers used patients many parties operating paragraph article imported parties operating paragraph article acknowledging parties operating paragraph article adopted metered dose inhaler transition strategies encouraged decision xii noting parties operating paragraph article yet put place national regional transition strategies parties produce metered dose inhalers unable finalize strategies unless technology conversion included national plans understanding therefore need measures facilitate transition non chlorofluorocarbon treatments asthma obstructive pulmonary disease parties operating paragraph article mindful cases regional approach transition may efficient noting parties operating paragraph article made substantial progress replacing chlorofluorocarbon metered dose inhalers alternative products present time still require limited amount pharmaceutical grade chlorofluorocarbons produce metered inhalers demonstrated current essential use exemption requests granted parties taking account decision xvii calls eighteenth meeting parties consider taking decision addressing difficulties faced parties operating paragraph article metered dose inhaler transition request executive committee multilateral fund implementation montreal protocol consider matter urgency funding projects relation parties operating paragraph article experience difficulties due high consumption chlorofluorocarbons manufacturing metered dose inhalers order facilitate transition chlorofluorocarbon metered dose inhalers request executive committee consider within context existing multilateral fund guidelines review decision regard existing cut off date consideration metered dose inhaler conversion projects consistent reality pace technological advances metered dose inhaler sector request implementation committee non compliance procedure montreal protocol consider possible options address potential non compliance difficulties parties operating paragraph article resulting high proportion chlorofluorocarbon consumption metered dose inhaler sector request implementation committee give special consideration situation parties particularly context paragraph non compliance procedure protocol light information received parties concerned due regard health considerations consider matter referred paragraphs twentieth meeting parties request executive committee consider including agenda united environment programme thematic regional workshops information clarify steps required advance transition chlorofluorocarbon metered dose inhalers request party operating paragraph article receiving essential exemptions production import chlorofluorocarbons manufacture metered dose inhalers export parties operating paragraph article submit importing party detailed export manufacturing transition plan manufacturer exports active ingredient party exceed metric tonnes specifying actions manufacturer taking take transition exports chlorofluorocarbon free metered dose inhalers expeditiously possible manner put patients risk manufacturer export manufacturing transition plans include specific details manufacturer export markets metered dose inhaler active ingredient concerning timing submission health authority marketing applications chlorofluorocarbon free alternatives expected approval launch alternatives withdrawal associated chlorofluorocarbon product products indicative information facilitative pricing licensing and or technology transfer arrangements consideration contribution to participation in programmes educating health care professionals government health authorities patients transition chlorofluorocarbon free treatments asthma chronic obstructive pulmonary disease consistent decision iv paragraph decision xii request party referred paragraph present decision deciding whether nominate essential use volumes and or grant essential use licenses manufacturer take account manufacturer efforts implement export manufacturing transition plan contribution transition towards chlorofluorocarbon free metered dose inhalers request party referred paragraph submit year technology economic assessment panel part party essential use nomination report summarizing export manufacturing transition plans submitted taking care protect confidential information request technology economic assessment panel consider reports assessment party essential use nominations request technology economic assessment panel assess report progress twenty seventh meeting open ended working group report nineteenth meeting parties need for feasibility of optimal timing of recommended quantities limited campaign production chlorofluorocarbons exclusively metered dose inhalers parties operating paragraph article parties operating paragraph article